Shanghai MicuRx Pharmaceutical Company Description

Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs.

It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resistant gram-negative bacteria; MRX-7 for multidrug-resistant gram-positive bacteria; MRX-15 and MRX-17 to treat kidney disease; MRX-18 for the treatment of COVID-19; and MRX-23 for the treatment of tumour.

The company was founded in 2007 and is based in Shanghai, China.

Shanghai MicuRx Pharmaceutical Co., Ltd.

Country	China
Founded	2007
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	151
CEO	Yuan Zhengyu

Contact Details

Address: 53, Edison Road Shanghai China
Phone	86 21 5090 0550
Website	micurxchina.com

Stock Details

Ticker Symbol	688373
Exchange	Shanghai Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	CNE100005PX4
SIC Code	2836

Key Executives

Name	Position
Dr. Yuan Zhengyu Ph.D.	Chief Executive Officer and Chairman
Xinghai Wang	Deputy GM, Chief Technology Officer and Director
Liang Lu	Chairman of the Supervisory Board, Director of Quality and Compliance Dept. & Dep. GM of Ops. Mgmt.
Hong Yuan	Deputy GM and Chief Clinical Officer
Youyin Xu	Deputy GM and Head of Commercial Operations
Anna Nie	Board Secretary
Cui Guo	Financial Controller and Head of Accounting Department
Liu Jingian	Head of Corporate Chemistry
Wang Wen	Head of Biological Department